European Heart Journal最新文献

{"title":"Data sharing statements: impact of journal policies across clinical research disciplines","authors":"Daniel Archer, Noah Barks, Mahad Chaudhry, Brody Dennis, Jacob Duncan, Annes Elfar, Taylor Gardner, Eli Paul, Micah Kee, Alicia Ito Ford, Matt Vassar","doi":"10.1093/eurheartj/ehaf359","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf359","url":null,"abstract":"Background and Aims Cardiovascular disease is a leading cause of mortality, with significant investments in research to improve treatment and prevention. Data sharing enhances transparency, reproducibility, and collaboration, yet data sharing statement (DSS) inclusion remains inconsistent. This study evaluates DSS prevalence, content, and influencing factors in high-impact cardiology journals, examines journal policy influence, and assesses data sharing feasibility by contacting authors who indicated data availability. Methods A cross-sectional analysis was conducted to assess DSS inclusion in top cardiology, selected general medicine, emergency medicine, and orthopaedic surgery journals. A systematic PubMed search identified clinical studies published from 2020 to 2023. Logistic regression models assessed factors associated with DSS inclusion, while thematic analysis categorized DSS content. Corresponding authors who indicated data availability upon request were contacted to evaluate follow-through. Results Among 2941 articles, 1004 (34.14%) included a DSS. Data sharing statement prevalence varied by discipline: cardiology (52%), general medicine (96%), emergency medicine (12%), and orthopedic surgery (14%). Policy enforcement drove DSS inclusion, with post-policy articles significantly more likely to contain a DSS. Funding status, study design, article access, and impact factor also influenced DSS presence. Thematic analysis identified conditional availability and gatekeeping as dominant DSS themes. Of authors who stated data were available upon request, only 31% ultimately provided access. Conclusions Data sharing statement inclusion in cardiology research remains inconsistent, with journal policies playing a key role in increasing prevalence. However, real-world data-sharing practices often fall short of stated commitments. Addressing logistical and financial barriers will be essential to improving data availability in cardiology research.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"50 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure: assessment of the global economic burden","authors":"Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M van Mieghem, Rudolf A de Boer, Jasper J Brugts, Robert M A van der Boon","doi":"10.1093/eurheartj/ehaf323","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf323","url":null,"abstract":"Background and Aims Heart failure (HF) is a major public health issue, imposing substantial costs on healthcare systems and societies. This study aimed to provide a contemporary overview of its global economic impact. Methods A systematic search of four databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies reporting direct cost (DC) and/or indirect cost (IC) associated with HF were included. DC and IC were expressed as a percentage of current healthcare expenditure (CHE) and gross domestic product (GDP), which were obtained for 2021 from the World Health Organization Global Health Expenditure Database. Countries were categorized by their Human Development Index (HDI), and weighted group means were calculated to estimate costs based on their 2021 expenditure. Results Thirty-two studies met the inclusion criteria. In 2021, the estimated economic burden of HF was $284.17 billion across 179 countries. This included $136.86 billion (48.16%) in DC and $147.31 (51.84%) billion in IC. Very high HDI countries account for most absolute HF spending, but HF comprises a smaller share of CHE and GDP (1.07% DC, 0.09% IC) compared with low HDI countries (8.85% DC, 0.29% IC). Conclusions The global economic burden of HF is substantial, increasing, and varies across countries. Although very high and high HDI countries carry most of the absolute costs, low HDI countries bear a disproportionate burden relative to their total healthcare expenditure or GDP. Data scarcity in these settings further impedes accurate burden estimates. To address this growing challenge, proactive and cost-effective measures tailored to each country’s healthcare system are crucial in optimizing HF care worldwide.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"2 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial","authors":"William A E Parker, Thomas A Nelson, Justin Lee, Heather M Judge, Ramzi A Ajjan, Johan Westerbergh, Agneta Siegbahn, Christina Christersson, John H Alexander, Renato D Lopes, Christopher B Granger, Elaine M Hylek, Lars Wallentin, Robert F Storey","doi":"10.1093/eurheartj/ehaf347","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf347","url":null,"abstract":"Background and Aims Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. Methods Plasma samples were obtained from anticoagulation-naïve participants, before initiation of study medication (n = 1841). Fibrin clot turbidimetry was performed, and lysis time determined. Associations between lysis time and characteristics, biomarkers, and on-treatment bleeding and cardiovascular events were assessed by lysis time quartile (Q1-4, shortest to longest). Results A shorter lysis time was associated with being older, male, permanent AF, lower body mass index, estimated glomerular filtration rate and C-reactive protein, and higher N-terminal pro-B-type natriuretic peptide. Major and clinically relevant non-major bleeding was significantly more frequent in lysis time Q1 vs. Q4 [6.3%/yr vs. 2.1%/yr; HR, 2.99 (95% CI, 1.75–5.12); P = .001], including after multifactorial adjustment [HR, 2.61 (1.45–4.69); P = .016]. Those in Q2 and Q3 had intermediate bleeding risk vs. Q4 [HR, 2.21 (1.27–3.87); 2.08 (1.18–3.66) respectively], suggesting a graduated effect. Treatment allocation to apixaban vs. warfarin did not affect the relationship between lysis time and bleeding (interaction-P = .80). There was no significant association between lysis time and a composite of cardiovascular death, stroke, systemic embolism or myocardial infarction. Conclusions Shorter pre-treatment fibrin clot lysis time independently predicted higher bleeding risk in patients receiving oral anticoagulation for AF.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"14 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive stenting of vulnerable plaques in diabetic patients: is it worth it?","authors":"Diana A Gorog","doi":"10.1093/eurheartj/ehaf267","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf267","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sepsis-induced cardiomyopathy.","authors":"Nadia Aissaoui, Florence Boissier, Michelle Chew, Mervyn Singer, Philippe Vignon","doi":"10.1093/eurheartj/ehaf340","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf340","url":null,"abstract":"<p><p>Sepsis remains the most common cause of death in critically ill patients worldwide and the most frequent non-cardiac disease diagnosed in the Coronary Care Unit. Myocardial dysfunction caused by sepsis, usually termed 'sepsis-induced cardiomyopathy' (SICM), is common and has long been a subject of interest for intensivists and cardiologists. Despite the lack of a consensus definition, SICM is widely recognized as a reversible condition characterized by acute single or bi-ventricular systolic and/or diastolic dysfunction unrelated to coronary artery disease. While indications for monitoring and treating septic cardiomyopathy are directed towards restoring tissue perfusion, a better understanding of the course and implications of septic cardiomyopathy may help to optimize interventions and improve clinical outcomes. The present review aims to summarize current knowledge on the epidemiology, pathophysiology and clinical presentation of SICM, and to provide insights to aid clinicians in managing affected patients.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising demand vs limited access: should cardiologists perform mechanical thrombectomy?","authors":"Peter Lanzer","doi":"10.1093/eurheartj/ehaf259","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf259","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial.","authors":"Min Chul Kim, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Do-Yoon Kang, Won-Jang Kim, Chang-Wook Nam, Jin-Ok Jeong, In-Ho Chae, Hiroki Shiomi, Hsien-Li Kao, Joo-Yong Hahn, Sung-Ho Her, Bong-Ki Lee, Tae Hoon Ahn, Kiyuk Chang, Jei Keon Chae, David Smyth, Gary S Mintz, Gregg W Stone, Youngkeun Ahn","doi":"10.1093/eurheartj/ehaf273","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf273","url":null,"abstract":"<p><strong>Background and aims: </strong>The efficacy and safety of preventive percutaneous coronary intervention (PCI) for treating vulnerable plaques in diabetic patients remain unclear.</p><p><strong>Methods: </strong>The PREVENT (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) trial was a randomized clinical trial that compared preventive PCI plus optimal medical therapy with optimal medical therapy alone in patients with non-flow-limiting (fractional flow reserve >0.80) vulnerable plaques identified via intracoronary imaging. Randomization was stratified by diabetes status. The primary endpoint was a composite of cardiac death, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularisation, or hospitalization for unstable or progressive angina at 2 years.</p><p><strong>Results: </strong>Among 1606 randomized patients, 490 (30.5%) had diabetes. Diabetic patients underwent PCI for non-target lesions before randomization more frequently than non-diabetics (40.6% vs. 33.8%, P = .009). There were no significant differences in the incidence of the primary endpoint between diabetic and non-diabetic patients [1.8% vs. 1.9%; hazard ratio 0.98; 95% confidence interval 0.45-2.14); P = .956]. However, the primary endpoint at 2 years was less frequent with preventive PCI compared with optimal medical therapy alone in both diabetic (0% vs. 3.7%; P = .004) and non-diabetic patients (0.5% vs. 3.2%; hazard ratio 0.16; 95% confidence interval 0.05-0.55; P = .004), without a significant interaction between diabetic status and randomized strategy.</p><p><strong>Conclusions: </strong>The risk of adverse clinical events was similar between diabetic and non-diabetic patients with non-flow-limiting vulnerable coronary plaques. However, preventive PCI was associated with a lower incidence of the primary endpoint at 2 years, regardless of diabetes status.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial","authors":"K Lance Gould, Nils P Johnson, Amanda E Roby, Richard Kirkeeide, Mary Haynie, Tung Nguyen, Linh Bui, Monica B Patel, Danai Kitkungvan, Patricia Mendoza, Dejian Lai, Ruosha Li, Stefano Sdringola, David McPherson, Jagat Narula","doi":"10.1093/eurheartj/ehaf356","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf356","url":null,"abstract":"Background and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI) compared with standard of care in chronic stable coronary artery disease (CAD). Methods Participants were randomly assigned to standard or comprehensive care groups. Rest-stress PET quantified CFC for physiological CAD severity at baseline, 2, 5, and up to 11 years. The comprehensive care group reviewed PET results with frequent clinic visits and open 24/7 phone/email support. Standard care lacked supportive contact with blinded PET results that were unblinded only for severely reduced CFC with high mortality risk for potential revascularization. Results Between 2009–2017, 515 patients were assigned to comprehensive care and 513 to standard care and followed for 5 or more years. Comprehensive vs standard care decreased risk factors and summed 5-year risk score (Δ−1.1 vs + 0.33; 95% confidence interval −1.84 to −0.97; P &amp;lt; .0001), decreased cumulative 11-year all-cause death (4.7% vs 8.2%; P = .023), death or MI (7.0% vs 11.1%; P = .024) late revascularization (9.5% vs 14.8%; P = .021) and major adverse cardiac events (29.5% vs 29.9%; P = .0006). Only 56 of 1028 (5.4%) CENTURY patients with chronic CAD had revascularization within 90 days predominantly guided by CFC severity. Conclusions The randomized CENTURY trial demonstrates that comprehensive integrated lifestyle modification and medical management towards goals with revascularization reserved for severely reduced CFC, significantly reduced risk factor scores, death, death or MI, and revascularization. ClinicalTrials.gov NCT00756379","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"49 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144165503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer?","authors":"Mattia Galli, Carlo Patrono","doi":"10.1093/eurheartj/ehaf346","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf346","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statins beat device-related in-stent neo-atherosclerosis: pathophysiology reigns supreme.","authors":"William Wijns, Shengxian Tu","doi":"10.1093/eurheartj/ehaf295","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf295","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}